Endoscopic intraductal radiofrequency ablation for extrahepatic cholangiocarcinoma: An update (2023)

Table 2 Comparative studies of endoscopic intraductal radiofrequency ablation with chemotherapy for extrahepatic cholangiocarcinoma

Ref.	Treatment	No. of patients	Location	Metastatic, %	ID-RFA catheter	Stent type	No. of ID-RFA applications	Stent patency period (median)		Progression free survival (median)		Overall survival (median)
Yang et al[16], 2020	S-1 chemotherapy + ID-RFA	37	Distal, Hilar	0	Habib	PS	3.3 (mean)	6.6 m	P = 0.014	12 m	P < 0.001	16.0 m	P < 0.001
	ID-RFA	38	Distal, Hilar	0	Habib	PS	2.4 (mean)	5.6 m		7 m		11.0 m
Gonzalez-Carmona et al[17], 2022	GEM-based chemotherapy + ID-RFA	40	Distal, Hilar	37.5	Habib	PS	1-21	NA	NA	12.9 m	P = 0.045	17.3 m	P = 0.004
	GEM-based chemotherapy	26	Distal, Hilar	50.0	Habib	PS	-	NA		5.7 m		8.6 m
Inoue et al[18], 2022	GEM with cisplatin + ID-RFA	25	Distal, Hilar	48	Habib	UMS	1.84 (mean)	10.7 m	P = 0.048	8.6 m	P = 0.014	17.1 m	P = 0.017
	GEM with cisplatin	25	Distal, Hilar	60	Habib	UMS	-	5.2 m		5.8 m		11.3 m

ID-RFA: Intraductal radiofrequency ablation; PS: Plastic stent; GEM: Gemcitabine; NA: Not applicable; UMS: Uncovered metal stent.